Progyny, Inc.

PGNY Healthcare Healthcare Plans

Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 5.30%, EPS grew 80.0% and free cash flow fell 12.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

26.86 0.60 −2.18%
Market cap
$2.1B
P/E
27.7×
Fwd P/E
19.9×
Dividend yield
—
F-score
8/9
Altman Z
8.89
Beneish M
−3.45
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

32.61 37.22 20.96 29.72
P/S ratio
1.46 1.71 1.06 1.72
P/FCF ratio
9.57 11.47 7.45 12.63
P/Operating CF
36.53 40.58 29.90 44.69
P/B ratio
3.31 4.26 3.13 4.97
EV/Sales
1.19 1.47 0.89 1.54
EV/EBITDA
16.14 20.99 11.33 17.15
EV/FCF
7.81 9.88 6.26 11.33
Current Ratio
2.96 2.73 2.13 2.14
Net Debt/EBITDA
(15.44) (18.22) (6.11) (5.69)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
3.07% 2.69% 4.77% 3.36%
Free Cash Flow Yield
10.45% 8.72% 13.42% 7.92%
Free Cash Flow per Share
0.53 0.57 0.49 0.57
Book value per Share
6.51 6.02 5.43 5.80
Free Cash Flow
45.99 48.59 39.60 44.21
EV/EBIT
17.60 22.21 11.96 18.03
Other line items

Show all line items

Columns are period end dates